{"url_path":"/sec/slxnw/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002761-index.html","accession_number":"0001178913-26-002761","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002761-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":77,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits\n\n \n\n(d) Exhibits\n\n[99.1](exhibit_99-1.htm)\n\n[Press Release, dated\nMay 18, 2026, titled “Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update”](exhibit_99-1.htm)\n\nSIGNATURE\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be\nsigned on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nSILEXION THERAPEUTICS CORP\n\n \n\n \n\nDate: May 18, 2026\n\nBy:\n\n/s/ Ilan Hadar\n\n \n\nName:\n\nIlan Hadar\n\n \n\nTitle:\n\nChief Executive Officer"}